

David J R Foster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11252569/publications.pdf>

Version: 2024-02-01

42
papers

1,495
citations

394421

19
h-index

315739

38
g-index

42
all docs

42
docs citations

42
times ranked

1610
citing authors

#	ARTICLE	IF	CITATIONS
1	Food, gastrointestinal pH, and models of oral drug absorption. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 112, 234-248.	4.3	197
2	Methadone <i>N</i> -demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 403-412.	2.4	161
3	Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 685-694.	4.7	119
4	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 287-297.	2.4	112
5	Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 427-440.	2.4	110
6	A Quantitative Review and Meta-Models of the Variability and Factors Affecting Oral Drug Absorption—Part I: Gastrointestinal pH. <i>AAPS Journal</i> , 2016, 18, 1309-1321.	4.4	90
7	Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5681-5696.	3.2	80
8	Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 742-755.	2.4	66
9	A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption—Part II: Gastrointestinal Transit Time. <i>AAPS Journal</i> , 2016, 18, 1322-1333.	4.4	58
10	Pharmacokinetic/Pharmacodynamic Modeling of Morphine and Oxycodone Concentrations and Analgesic Effect in a Multimodal Experimental Pain Model. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 619-631.	2.0	54
11	ABCB1 haplotype and OPRM1 118A & G genotype interaction in methadone maintenance treatment pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 53.	0.7	39
12	Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 274-284.	2.5	36
13	An introduction to physiologically-based pharmacokinetic models. <i>Paediatric Anaesthesia</i> , 2016, 26, 1036-1046.	1.1	29
14	Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. <i>Pharmaceutical Research</i> , 2016, 33, 1782-1794.	3.5	27
15	Pharmacokinetic/Pharmacodynamic Relationships of Cognitive and Psychomotor Effects of Intravenous Buprenorphine Infusion in Human Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 94-101.	2.5	26
16	Cerebral kinetics of oxycodone in conscious sheep. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 1666-1676.	3.3	24
17	A Pharmacokinetic and Pharmacodynamic Study of Oral Oxycodone in a Human Experimental Pain Model of Hyperalgesia. <i>Clinical Pharmacokinetics</i> , 2010, 49, 817-827.	3.5	24
18	(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 895-902.	2.4	23

#	ARTICLE	IF	CITATIONS
19	Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 404-413.	2.4	20
20	Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 1153-1159.	1.9	19
21	Genetic polymorphism of <i>CYP1A2</i> but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 113-123.	2.4	19
22	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 536-541.	2.4	17
23	Stereoselective Quantification of Methadone and a d6-labeled Isotopomer Using High Performance Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass-Spectrometry: Application to a Pharmacokinetic Study in a Methadone Maintained Subject. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 559-567.	2.0	15
24	Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 326-335.	2.4	15
25	Simple HPLC method for determination of rosiglitazone in sheep plasma and amniotic fluid and its application in a pregnant sheep model. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 55, 360-365.	2.8	14
26	Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 263-276.	2.5	13
27	A physiologically-based recirculatory meta-model for nasal fentanyl in man. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 561-576.	1.8	11
28	Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 201-215.	1.6	9
29	Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1073-1087.	2.3	8
30	Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 924-934.	2.4	8
31	The Acute Disposition of (R)- and (S)-Methadone in Brain and Lung of Sheep. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 547-570.	1.8	7
32	Pharmacokinetic-Pharmacodynamic Modelling of the Analgesic and Antihyperalgesic Effects of Morphine after Intravenous Infusion in Human Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 115, 257-267.	2.5	7
33	Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method. <i>Drugs in R and D</i> , 2017, 17, 189-198.	2.2	7
34	ADVAN-style analytical solutions for common pharmacokinetic models. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 73, 42-48.	0.7	5
35	Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 181-197.	1.8	5
36	Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory Depression. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 720-729.	4.7	5

#	ARTICLE	IF	CITATIONS
37	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 777-788.	2.4	4
38	Blood-brain equilibration kinetics of levo- α -acetyl-methadol using a chronically instrumented sheep preparation. <i>British Journal of Pharmacology</i> , 2006, 147, 209-217.	5.4	3
39	Modelling the PKPD of oxycodone in experimental pain – Impact of opioid receptor polymorphisms. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 86, 41-49.	4.0	3
40	Pharmacometrics in Australasia – Twenty Years of Population Approach Group of Australia and New Zealand. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 701-704.	2.5	3
41	Molecular Modeling Approaches for the Prediction of Selected Pharmacokinetic Properties. <i>Current Topics in Medicinal Chemistry</i> , 2019, 18, 2230-2238.	2.1	2
42	A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1046-1057.	2.4	1